Search clinical trials for: Aranesp (darbepoetin alfa)

Total 3070 results

Region Stockholm

Not yet recruiting

The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy (FOXTROT)

Diabetes Complications | Diabetes; Nephropathy (Manifestation)

Sweden
Biocad

Completed

The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

Healthy

Russian Federation
Amgen

Completed

An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)

Kidney Disease
Royal Alexandra Hospital
University of Alberta

Completed

Safety of Darbepoetin Alfa Treatment in Patients With Severe Traumatic Brain Injury

Traumatic Brain Injury

Canada
Amgen

Completed

Darbepoetin Alfa MDS Companion Protocol

Myelodysplastic Syndrome (MDS)

Belgium
University of Washington
Amgen

Completed

Study of Aranesp to Treat Anemia in Prostate Cancer Patients.

Anemia | Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Recruiting

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Myelodysplastic Syndromes

United States
UMC Utrecht
The Hospital for Sick Children; Alberta Children's Hospital

Recruiting

Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration (DINOSAUR)

Perinatal Stroke | Neonatal Stroke | PAIS

Netherlands
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Terminated

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Neoplasms | Cancer | Anemia

United States
Amgen

Terminated

Study of South African Dialysis Patients

Chronic Kidney Disease, Receiving Dialysis

South Africa
Amgen

Completed

A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®

Anemia
Dartmouth-Hitchcock Medical Center
Amgen

Completed

A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer

Cancer | Anemia

United States
Biocad

Completed

Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

Reticulocyte Count
University of Maryland, Baltimore
Amgen

Completed

Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease

Anemia | Chronic Kidney Disease | Cardiomyopathy

United States
Sanquin-LUMC J.J van Rood Center for Clinical Transfusion...
Leiden University Medical Center

Unknown

EPO-4-Rhesus Study (EPO-4-Rhesus)

Erythroblastosis, Fetal | Erythroblastosis Fetalis, Rh Disease | Erythroblastosis Fetalis Due to RH Antibodies | Erythroblastosis Fetalis Due to Isoimmunization

Netherlands
Amgen

Completed

Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease (START-CKD)

Anemia in Chronic Kidney Disease Patients Not on Dialysis

United States, Puerto Rico
Amgen

Completed

Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

MDS

Germany, Italy, Belgium, Czechia, Switzerland, France, Austria, Greece, Spain
Amgen

Completed

Study to Evaluate Effectiveness of Aranesp®

Kidney Disease
Amgen

Terminated

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Cancer | Anemia | Non-Small Cell Lung Cancer | Lung Cancer

United States, Belgium, Italy, Poland, Switzerland, Canada, Germany, Russian Federation, China, Taiwan, United Kingdom, Hong Kong, Austria, Brazil, Israel, South Africa, Czechia, Greece, Spain, Netherlands, Bulgaria, Romania, Ireland, Puerto Rico and more
Sir Charles Gairdner Hospital

Completed

Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients

Anemia | Kidney Failure, Chronic

Australia
University of New Mexico
University of Colorado, Denver; Thrasher Research Fund; Intermountain Health...

Completed

Darbepoetin Administration to Preterm Infants

Infant, Newborn

United States
Amgen

Withdrawn

Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease

Anemia | Chronic Kidney Disease
Amgen

Completed

Study of Transplant Related Anemia Treated With Aranesp® (STRATA)

Anemia
Amgen

Completed

Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis

Anemia | Chronic Renal Failure
Hoffmann-La Roche

Completed

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Chronic Renal Anemia

Belgium, Brazil, United Kingdom, Serbia, Spain, Germany, Korea, Republic of, Turkey, Lithuania, Italy, Czechia, Argentina, Australia, Croatia, France, Greece, Israel, Malaysia, Mexico, Panama, Philippines, Poland, Russian Federation, ... and more
Amgen

Completed

A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia

Neoplasms | Anemia
Amgen

Terminated

Darbepoetin Alfa and Anemia of Cancer

Neoplasms | Carcinoma | Cancer | Anemia | Non-Myeloid Malignancies | Anemia of Cancer
University of Liege
KU Leuven; Amgen; Vrije Universiteit Brussel

Completed

Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)

Hematological Malignancies

Belgium
Amgen

Completed

Aranesp® Monthly Preference Study - 2

Kidney Disease
Biocad

Completed

Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers

Healthy

Russian Federation
Seoul National University Bundang Hospital
SMG-SNU Boramae Medical Center

Terminated

Effect of Darbepoetin in Contrast-induced Nephropathy

Acute Kidney Injury

Korea, Republic of
Dong-A ST Co., Ltd.

Completed

A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen)

Symptomatic Anemia

Netherlands
University of Pennsylvania

Completed

The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial (DISC)

Stroke | Neuroprotection | Spinal Ischemia

United States
Amgen

Completed

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

Cancer | Anemia
Institut Claudius Regaud

Terminated

Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced

Neoplasms | Anemia

France
Amgen

Completed

ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer

Breast Cancer
Amgen

Completed

STAAR-2 Clinical Study

Chronic Kidney Disease | Chronic Renal Insufficiency | Kidney Disease | Pre-dialysis | Pre-ESRD
Andrea L Woodland

Completed

Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients

Anemia | Chronic Kidney Disease
Amgen

Completed

STAAR-3 Clinical Study

Chronic Kidney Disease | Chronic Renal Insufficiency | Kidney Disease | Pre-dialysis | Pre-ESRD
Amgen

Completed

Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis

Kidney Disease
Amgen

Terminated

Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease

Anemia | Chronic Kidney Disease | Kidney Disease

United States, Belgium, Mexico, United Kingdom, Puerto Rico, Poland, Russian Federation, Latvia, Lithuania, Slovakia
Hoffmann-La Roche

Completed

A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients

Anemia

Italy, Spain, Australia, France, Canada, Germany, United Kingdom, Belgium, Austria, Switzerland, Netherlands, Denmark, Finland, Portugal
Amgen

Completed

RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

Heart Failure | Cardiovascular Disease | Anemia | Ventricular Dysfunction | Congestive Heart Failure

United States, France, Germany, Italy, Netherlands, Spain, United Kingdom, Belgium, Czechia, Denmark, Hungary, Canada, Australia, Hong Kong, South Africa, Chile, Austria, Puerto Rico, Slovakia, Argentina, Israel, Russian Federation, Polan... and more
Amgen

Completed

Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis

End Stage Renal Disease
Akebia Therapeutics

Completed

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

Anemia | Non-Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Korea, Republic of, Australia, New Zealand, South Africa, United Kingdom, Spain, Ukraine, Hungary, Israel, Bulgaria, Russian Federation, Mexico, Poland, Brazil, Argentina, Malaysia, Puerto Rico, France
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Canada, Korea, Republic of, United Kingdom, Australia, Germany, Israel, France, Portugal, Bulgaria, Russian Federation, Ukraine, Poland, Brazil, Argentina, Mexico, Serbia
Amgen

Terminated

STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients

Anemia | Chronic Kidney Disease
Barts & The London NHS Trust
Cancer Research UK; Amgen

Unknown

Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes (REGIME)

Myelodysplastic Syndrome

United Kingdom
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Anemia | Non-Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Spain, Czechia, Korea, Republic of, Malaysia, Australia, New Zealand, United Kingdom, Germany, Turkey, Ukraine, France, Hungary, Austria, Israel, Bulgaria, Russian Federation, Romania, Slovakia, South Africa, Canad... and more
Amgen

Completed

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Anemia | Non-Myeloid Malignancies

Search clinical trials for: Aranesp (darbepoetin alfa)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations